Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc Reaffirms FY 2013 Guidance

Thursday, 24 Oct 2013 05:33pm EDT 

Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects total revenues in $530 million to $555 million range, GAAP net loss of $(185) to $(160) million and non-GAAP adjusted EBITDA (loss) of $(65) to $(40) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $551 million for fiscal 2013. 

Company Quote

1 Jun 2015